CCKR THERAPEUTICS INC

From the company

CCKr Therapeutics is a drug development company focused on transforming GI cancer and fibrosis treatment. Its lead asset, Proglumide, is a small molecule repurposed drug with oral bioavailability that antagonizes the CCK-B receptor and blocks CCK-A and CCK-B receptors. Target indications include pancreatic cancer, chronic pancreatitis, liver fibrosis, and pain management. The company reports early Phase 1 results and ongoing Phase 1/2 trials, with fast-track potential.